Start a new week with a brief recap of the investment financing deals disclosed last week.
Among the newly disclosed financings in the field of consumer services, the catering track completed 1 financing. Non-stop Technology received nearly 100 million yuan in A+ round of financing, led by Huashan Capital.
Among the newly disclosed financings in the field of medicine and health, the biomanufacturing track has completed 5 financings. Antikang Biotech completed a round of financing of more than 200 million yuan, co-led by Simcere Pharmaceutical, Huajin Investment and Huajin Avenue; Tuoji Pharmaceutical completed a Pre-A round of financing of over 100 million yuan, with exclusive investment from Decheng Capital.
Among the newly disclosed financings in the technology and manufacturing sector, a number of financings have been completed in the advanced manufacturing sector. Tingyu Technology completed hundreds of millions of yuan in Series B financing, co-led by Guohai Investment and Fosun Ruizheng; Huahao Weiye completed 40 million A round of financing, and Dunhong Asset Investment.
21 Venture Capital incomplete statistics, from June 24 to June 30, there were 15 financing events in the domestic primary market during the reporting date. Among them, 14 financings disclosed financing amount and currency information, with a total scale of more than 910 million yuan.
01. Completed a number of financings in the medical and health field
This week, biomanufacturing, medical equipment and other sub-tracks completed 5 and 3 financings respectively, with a financing amount of more than 716 million yuan, far ahead of other tracks. In addition, the advanced manufacturing track completed 4 financings this week.
02. Jiangsu Province and Guangdong Province completed a number of financings
Judging from the geographical distribution of the disclosed invested companies, this week's financing areas are mainly concentrated in Jiangsu Province and Guangdong Province, with 7 and 3 financings completed respectively.
03. Which investment institutions are more active
From the perspective of institutional investment activity, GSR United Capital, Cornerstone Fund and Frees Capital were more active this week, each completing one financing, mainly in the field of technology manufacturing.
The following is a summary of investment and financing information:
Consumption of services
Non-stop Technology received nearly 100 million yuan in A+ round of financing, led by Huashan Capital
On June 28, it was reported that Shenzhen Non-stop Technology Co., Ltd. (hereinafter referred to as "Non-stop Technology") recently completed nearly 100 million yuan in A+ round of financing, which was led by Huashan Capital (WestSummit Capital), and the old shareholder Professor Gao Bingqiang Ecosystem Fund Future Technology participated in the investment, and the old shareholder Professor Li Zexiang's Clear Water Bay Fund and Professor Gan Jie's Zhixing No. 1 Fund continued to exceed the quota for three consecutive rounds. Centron Capital acted as the exclusive financial advisor for the follow-on financing. This round of funds will be used for product development and global delivery.
Founded in 2021, the company provides an overall AI digital kitchen solution integrating software and hardware for the global market, and digitizes the whole process of the kitchen scene through products such as intelligent cooking robots and intelligent kitchen scheduling systems, ensuring the consistency of dishes, helping catering companies reduce labor costs, alleviate the problem of labor shortage, and improve operational efficiency and large-scale chaining speed.
Healthcare
Weibang Zhendian completed nearly 100 million yuan in Series A+ financing, led by Daoyuan Capital
On June 24, Suzhou Weibang Zhendian Optoelectronics Technology Co., Ltd. (hereinafter referred to as "Weibang Zhendian") announced the completion of nearly 100 million yuan in A+ round of financing, led by Daoyuan Capital, the old shareholder Fengrui Capital over-invested, and Founder Hesheng followed. This round of funds will be used to promote the rapid commercialization of Weibang Zhendian's spectral analysis products, the iterative development of solutions in the industrial field, and the research and development of ultra-multiplex immunohistochemistry applications. Yuanyi Capital acted as the long-term exclusive financial advisor to Weibang Zhendian.
Founded in 2017, Weibang Zhendian includes Zhendian (Suzhou) Medical Technology Co., Ltd. and Weipeng (Suzhou) Medical Device Co., Ltd. The company has won the national high-tech enterprise qualification, the title of Suzhou Industrial Park Science and Technology Leading Talent, and the second prize of China Medical Device Innovation and Entrepreneurship Competition. The company's core team has many years of R&D accumulation in the fields of spectroscopy, optical imaging, photoelectric analysis, etc., and has independent and controllable leading technical capabilities around the world, and has more than 10 independent research and development core patents and 16 exclusive authorized patents from world-renowned scientific research institutions. The company has more than 1,000 square meters of R&D and production sites, has a sound design and development system and quality control system, and has obtained medical device quality system certification and GMP system certification.
Antikang Biotech completed a round A financing of more than 200 million yuan, co-led by Simcere Pharmaceutical, Huajin Investment and Huajin Avenue
On June 25, it was reported that Jiaxing Antikang Biotechnology Co., Ltd. (hereinafter referred to as "Antikang Biotechnology") officially announced the completion of a round of financing of more than 200 million yuan, which was launched by Simcere Pharmaceutical (02096. HK), Huajin Investment and Huajin Avenue jointly led the investment, the old shareholders Tongchuangweiye and Jiaxing New Venture Capital continued to increase investment, and Jiarui Future Star, GSR United Runpu Medical Fund, Wenzhou Investment, Songze Capital and Shunjie Health followed. The funds raised will be used for the preclinical and clinical stage development of Anticon's core product pipeline, in particular, to accelerate the clinical trial and commercialization progress of the self-developed anti-influenza class 1 new drug deuternoxavir (code name ADC189) tablets and granules for children.
Founded in 2018, Antikang Biotech is an innovative pharmaceutical company focusing on the development of innovative therapeutic drugs in the field of respiratory infections and pain. The company's scientific and technological innovation team is led by a number of academicians, bringing together a group of academically professional, efficient and pragmatic high-level talents, forming high technical barriers at different stages of new drug creation, such as innovative drug design and synthesis, DMPK technology research and application, and research and development of high-end preparations suitable for special populations, and has formed a small molecule innovative treatment new drug research and development system based on metabolic differentiation.
Baifu Laser received tens of millions of yuan in Series B financing and invested in Daxing Airport Zone Development Fund
On June 27, Suzhou Baifu Laser Technology Co., Ltd. (hereinafter referred to as "Baifu Laser") recently announced the completion of tens of millions of yuan in Series B financing, which was invested by Beijing Xinhangcheng Fund Management Co., Ltd. ("Xinhangcheng Fund Company"), a subsidiary of Beijing Xinhangcheng Holdings Co., Ltd. ("Xinhangcheng Fund Company"), and Zhoudu Capital served as the exclusive financial advisor for this round of financing.
Since its establishment in 2021, Baifu Laser has received an investment of more than 100 million yuan from well-known investors such as Northern Light Venture Capital and Yuansheng Venture Capital. This round of investment funds will be used for the research and development and declaration of new products, the expansion of overseas markets and brand building, and the initial construction of domestic channels, so as to accelerate the global layout of Baifu Laser's self-developed equipment.
Tuoji Pharmaceutical completed a Pre-A round of financing of over 100 million yuan, with exclusive investment from Decheng Capital
On June 27, Phrontline Biopharma, a leading bispecific antibody ADC company in China, announced the completion of a Pre-A round of financing of more than 100 million yuan, which was exclusively invested by Decheng Capital and Index Capital served as the exclusive financial advisor. After this round of financing, Tuoji will increase R&D investment, accelerate the advancement of multiple preclinical pipelines, upgrade its own technology platform, and accelerate towards the vision of "becoming the world's leading pharmaceutical company".
Founded in early 2022, Tuoji Pharmaceutical is determined to be a source of innovative ADC drugs. Its independent technology platform covers the four core technologies of ADC drugs (toxin, linker, conjugation method, antibody), and has rapidly established advanced antibody discovery and bispecific antibody preparation platform, Linker-Payload design and synthesis platform, and site-specific quantitative conjugation technology platform.
Weiyuan Biotech completed tens of millions of yuan in angel round financing
On June 27, it was reported that Hangzhou Weiyuan Biotechnology Co., Ltd. (hereinafter referred to as "Weiyuan Bio") completed an angel round of financing of tens of millions of yuan, and this round of financing has been strongly supported by a number of industrial funds, and the funds raised will be mainly used to accelerate the transformation and upgrading of the company's chiral compound pilot platform and natural product efficacy evaluation system, and promote the commercialization process of key projects. This will help accelerate the further optimization and engineering transformation of the company's technical system, and inject strong impetus into the company's sustainable development in the future.
As an innovative biotechnology high-tech enterprise composed of senior bioengineers, enzyme engineering experts and operational elites in the digital industry, the team of Weiyuan Biotech brings together outstanding talents graduated from Tsinghua University, Zhejiang University, Zhejiang University of Technology, Hainan University, Ocean University of China and other well-known universities, who have profound professional background and experience in the field of pharmaceutical and high value-added chemical biomanufacturing engineering and technological innovation.
Topai Medical completed a Series D financing of 200 million yuan, led by Matrix Partners
On June 28, it was reported that Tupai Medical, a leading company in China's high-end ophthalmic medical equipment, completed a 200 million yuan D round of financing, which was led by Jingwei Venture Capital and followed by Gaotejia Investment and other institutions.
Founded in 2017, the core technology of Tupai Medical originates from the transformation of Tsinghua University's scientific and technological achievements, and the core technical team is composed of dozens of Tsinghua teachers, students and alumni. Since its establishment, the company has achieved breakthroughs in the field of high-end ophthalmic devices in multiple categories through the vertical integration of ophthalmic clinical needs, innovative system functions and high-performance upstream devices.
Shixi Biotech completed tens of millions of yuan in angel+ round financing, co-led by Beijing Life Park Venture Capital, Tiantu Investment and Yayi Capital
On June 28, it was reported that the nucleic acid drug research and development company "Shixi Biotechnology" recently completed the first round of financing of tens of millions of yuan angel+. This round of financing was co-led by Beijing Life Park Venture Capital, Tiantu Investment and Yayi Capital, followed by BeiGene Bio Island Innovation Center, with Xiaochi Capital continuing to invest, and Haoyue Capital serving as the exclusive financial advisor. This round of financing will be used for the research and development of the company's core projects, clinical application and team replenishment.
Founded in December 2021 by relying on the laboratory of Professor Zhang Rui of the School of Life Sciences of Sun Yat-sen University, Shixi Biotech is located in the BeiGene Innovation Center on Guangzhou Bio Island. Based on RNA editing technology, the first pipeline under development of Shixi Biotech is mainly aimed at neurological diseases, and has completed molecular research, is in the preclinical stage, and is expected to apply for IND in 2025. The follow-up pipeline will focus on cardiovascular and cerebrovascular diseases, nervous system diseases, respiratory diseases, anti-aging and other directions.
Enzyme Technology received tens of millions of yuan in angel round financing, led by linear capital
On June 28, it was reported that Enzyme Technology has completed an angel round of investment of tens of millions of yuan, led by Linear Capital, followed by MiraclePlus and Danen Capital. This round of financing will be mainly used for the promotion of experiments related to enzymatic DNA synthesis, instrument research and development, and team building.
Founded in March 2023, Enzyme Technology is committed to establishing protein-nucleic acid interaction algorithms and designing enzyme molecular machines to efficiently synthesize DNA, which can synthesize genes de novo at low cost and on a large scale, so as to obtain a large number of high-quality biological macromolecule data and connect large models with the microscopic molecular world.
Technology & Manufacturing
Tingyu Technology completed hundreds of millions of yuan in Series B financing, co-led by Guohai Investment and Fosun Ruizheng
On June 24, it was reported that the real-time interactive edge cloud service provider "Tingyu Technology" announced the completion of hundreds of millions of yuan of Series B financing jointly led by Guohai Investment and Fosun Ruizheng, followed by Cornerstone Information Innovation, Zhongxiang Venture Capital, Honghu Zhiyuan Investment, Sichuan Cultural Investment, Sanqi Mutual Entertainment, Ingenuity Investment, etc., and this round of financing was served by Yiwei Capital as the exclusive financial advisor. According to reports, the funds will be used to continuously iterate the research and development of its real-time interactive cloud core technology, as well as to explore the application and implementation of real-time interactive computing power in AI training and inference.
Founded in 2019, Tingyu Technology's core product is a self-developed real-time interactive distributed edge computing cloud platform. By integrating national heterogeneous edge servers, the company has built a computing resource pool based on the edge side, providing high-performance, high-reliability, high-elasticity and low-cost cloud computing power for the three major industry application scenarios of real-time entertainment, real-time office and AGI, helping customers improve the interactive experience of users in the process of use.
DreamTech completed the angel + round of financing of tens of millions of yuan, with exclusive investment from Chuxin Capital
On June 25, it was reported that the AI startup company "DreamTech" has continuously completed tens of millions of yuan in angel rounds and angel + rounds of financing, the angel round is led by Oriza Origin, followed by TusStar Venture Capital and Cloud Angel Fund, and the angel + round is the exclusive investment of Chuxin Capital. Just as the advancement of large language model technology has directly promoted the wave of text-generating AI such as ChatGPT, in the fields of images, videos, and 3D, large model technology has also promoted the progress of generative AI, including 2D and 3D.
"DreamTech" is an AI startup focused on native 3D generation, and the company began official operations in December 2023. CEO Dr. Zhang Feihu graduated from the University of Oxford, and the founding members of the team include academicians of the British Academy of Sciences and the Chinese Academy of Sciences, national young talents, founding members of Tencent Meeting, etc., and have worked in leading companies in the industry such as Apple, Tencent, and Baidu. The founding team members have successfully founded a number of companies that have become benchmarks in the 3D field, which have been acquired by industry giants such as Apple, Google, and Bosch.
AdvanSol received angel+ round of financing and was invested by Qingrui Venture Capital
On June 25, it was reported that recently, the domestic third-generation inverter and MLPE (module-level management) company Aichang Huizhi (Suzhou) New Energy High Technology Co., Ltd. (hereinafter referred to as "Aichang Huizhi AdvanSol") completed the angel + round of financing. This round of financing was invested by Qingrui Venture Capital. The funds raised will be used for product research and development and talent recruitment to further enhance the comprehensive competitiveness of the enterprise.
Founded in August 2023, AdvanSol is a R&D and manufacturer of third-generation inverter system solutions, committed to creating a cost-effective third-generation microstring inverter technology with independent intellectual property rights.
Hangkai Microelectronics received tens of millions of yuan in angel round financing, and FreeS Capital exclusively invested
On June 26, it was reported that "Hangkai Microelectronics" has recently completed an angel round of financing of tens of millions of yuan. This round of financing was exclusively invested by Frees Capital, with Kaiyuan Capital acting as the exclusive financial advisor. The funds raised will be mainly used for product research and development, market expansion and team size expansion. "Hangkai Microelectronics" focuses on the research and development of force-related sensors, and the company's products include silicon-based MEMS accelerometers, multi-dimensional force sensors (six-dimensional force sensors), etc.
Founded in October 2021, Hangkai Microelectronics currently has more than 10 members in the team, of which more than 90% are technical R&D personnel, which also lays the foundation for the company's independent research and development of multi-dimensional force sensors.
Huahao Weiye completed a round of financing of 40 million yuan, and Dunhong Asset Investment
On June 28, it was reported that Shenzhen Huahao Weiye Optoelectronics Co., Ltd. (hereinafter referred to as "Huahao Weiye") recently completed a round of financing of 40 million yuan, and the investors are Dunhong Assets and Guoxin Venture Capital. This round of funds is mainly used for capacity expansion, new product research and development, and market expansion.
Founded in 2014, Huahao Weiye has three product lines, including automotive semiconductors, Mini backlights and plant backlights. After accumulating nearly ten years of high-performance LED design and packaging technology precipitation, the company has officially entered the automotive grade LED track, with products covering exterior lighting, interior atmosphere and vehicle screens, and is one of the first batch of enterprises in China to officially enter the list of first-tier car enterprise suppliers.
Qingguan Technology completed tens of millions of angel round financing, and Yonggui Fund invested
On June 28, Qingguan Technology recently announced the completion of an angel round of financing of tens of millions of yuan, and the investor is Yonggui Fund. In this round of financing, Qingguan Technology will be used for the construction of demonstration production lines and technology research and development.
Founded in 2022, Qingguan Technology focuses on the R&D, production and application of new thermal insulation and energy-saving materials, nano-aerogels, and new thermal management technologies. The founder is Dr. Ma Guanxiang, the leader of the nano aerogel team of the Institute of Process Engineering, Chinese Academy of Sciences, and has many years of experience in the research and development of aerogel materials and the application of thermal protection technology.
For more information, please download the 21 Finance APP